Charles River Laboratories (CRL)vsThermo Fisher Scientific Inc (TMO)
CRL
Charles River Laboratories
$277.33
-2.73%
HEALTHCARE · Cap: $13.39B
TMO
Thermo Fisher Scientific Inc
$658.52
+1.03%
HEALTHCARE · Cap: $225.48B
Smart Verdict
WallStSmart Research — data-driven comparison
Thermo Fisher Scientific Inc generates 1059% more annual revenue ($46.34B vs $4.00B). TMO leads profitability with a 15.0% profit margin vs -6.0%. CRL appears more attractively valued with a PEG of 0.12. TMO earns a higher WallStSmart Score of 60/100 (C+).
CRL
Hold43
out of 100
Grade: D
TMO
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-2.1%
Fair Value
$162.50
Current Price
$277.33
$114.83 premium
Margin of Safety
-88.3%
Fair Value
$345.90
Current Price
$658.52
$312.62 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Mega-cap, among the largest globally
Generating 1.7B in free cash flow
Areas to Watch
Elevated debt levels
ROE of -8.4% — below average capital efficiency
Revenue declined 2.7%
Earnings declined 17.3%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CRL
The strongest argument for CRL centers on PEG Ratio. PEG of 0.12 suggests the stock is reasonably priced for its growth.
Bull Case : TMO
The strongest argument for TMO centers on Market Cap, Free Cash Flow. Revenue growth of 10.5% demonstrates continued momentum.
Bear Case : CRL
The primary concerns for CRL are Debt/Equity, Return on Equity, Revenue Growth.
Bear Case : TMO
The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
CRL profiles as a turnaround stock while TMO is a value play — different risk/reward profiles.
CRL carries more volatility with a beta of 1.41 — expect wider price swings.
TMO is growing revenue faster at 10.5% — sustainability is the question.
TMO generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
TMO scores higher overall (60/100 vs 43/100) and 10.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Charles River Laboratories
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
Thermo Fisher Scientific Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?